Forms Processing

WHITE PAPERS AND CASE STUDIES

• Peace River Manasota Regional Water Supply Authority Uses Powdered Activated Carbon To Ensure High Quality Drinking Water

  Founded in 1982, Peace River Manasota Regional Water Supply Authority supplies drinking water to a region of approximately one million people. Its surface water treatment plant draws water from the Peace River to a reservoir and treats it to drinking water standards at the rate of about 31 million gallons a day.

• How Advanced Biological Technologies Overcome Complex Wastewater Treatment Challenges In The Oil And Gas Sector

  This white paper explores how advanced biological technologies — including MBBR, IFAS, SBR, and MBR systems — are transforming wastewater management in this sector.

• MilliporeSigma's 97-Day Implementation Success Story

  Read how MilliporeSigma transformed validation processes with a digital validation system to achieve compliance in just 97 days, as well as learn key takeaways from their swift transition.

• A Risk-Based Approach To Plasmid DNA And mRNA Process Development

  Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.

• How A Pharma Company Improved Yield By 1.5% In Just Three Months

  A pharma company faced a 4% yield drop and variability at a manufacturing facility. Explore how they leveraged an AI-based platform to unify data, pinpoint inefficiencies, and enhance consistency in yields.

• Improving The eCOA Experience

  Discover how template-driven builds and reuse can slash eCOA timelines by 50% while solving the licensing and translation hurdles that delay First Patient In.

• Everest Group Life Sciences eCOA Peak Matrix Assessment 2025

  Discover how digital platforms are revolutionizing clinical trials by improving data quality and patient engagement in this comprehensive market assessment.

• Flexible Fill/Finish Solutions To Bridge The Clinical-To-Commercial Gap

  As biopharma complexity grows, flexible CDMOs are essential for navigating evolving fill/finish needs, accelerated timelines, and regulatory uncertainty with agility and expertise.

• Transitioning Your Product From Phase 1 To Phase 2 Clinical Studies

  Strategic partnerships can streamline your transition from Phase 1 to Phase 2 clinical studies, ensuring optimized dosage forms, seamless scale-up, and alignment with patient and study requirements.

• Hunting An Unexpected mAb Variant With LC‑MS

  A tailored LC–MS approach enables sensitive detection and tracking of monoclonal antibody variants, supporting deeper product characterization and better control of quality‑impacting changes.

• Implementation of the New European Health Technology Assessment Regulation (HTAR)

  The European Health Technology Assessment Regulation (HTAR) requires joint clinical assessments for certain therapies starting 2025, impacting market access preparation for companies in the EU.

• Catalent's Journey Of Continuous Improvement For CSV Excellence

  Learn how organizations must continuously reassess validation processes and digital tools to ensure compliance, enhance efficiency, and support global scalability amidst evolving regulatory expectations.